Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prognostic risk assessment marker for B-ALL (acute lymphoblastic leukemia) patient

A risk assessment and patient technology, applied in the direction of recombinant DNA technology, microbial measurement/testing, biochemical equipment and methods, etc., can solve problems such as patient recurrence

Active Publication Date: 2017-11-03
PEOPLES HOSPITAL PEKING UNIV
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is worth noting that some of the standard-risk patients still relapsed, suggesting that the current risk stratification still needs to be refined, so the discovery and verification of new prognostic molecular markers is necessary for more accurate risk stratification , and may provide therapeutic targets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prognostic risk assessment marker for B-ALL (acute lymphoblastic leukemia) patient
  • Prognostic risk assessment marker for B-ALL (acute lymphoblastic leukemia) patient
  • Prognostic risk assessment marker for B-ALL (acute lymphoblastic leukemia) patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1. DIAPH1 gene mutation and B-ALL patient prognosis risk assessment

[0055] 1. Research object

[0056] A total of 226 patients with newly diagnosed B-ALL in Peking University People's Hospital from April 2007 to December 2015 were collected as the research group. Inclusion criteria: ① age ≥ 14 years old; ② meet the B-ALL standard diagnosis (refer to WHO classification criteria for precursor B and T cell tumors); ③ all newly diagnosed, without any relevant treatment. The patient or the patient's guardian (if the patient's age is <18 years old) signed the informed consent. This study was approved by the Medical Ethics Committee of Peking University People's Hospital and complied with the Declaration of Helsinki. The cut-off time for the observation of patients is April 30, 2016.

[0057] 2. Treatment plan

[0058] All patients received induction chemotherapy (1-2 courses in total), and if the patient achieved complete remission, 2 courses of consolidation ch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a prognostic risk evaluation marker for a B-ALL (acute lymphoblastic leukemia) patient. The invention protects application of a product used for detecting a DIAPH1 gene or a product for detecting DIAPH1 gene mutation in a preparation kit; the use of the kit is at least one of the following (a1)-(a4): (a1) prognostic risk assessment in a patient with B-ALL; (a2) evaluation of a prognostic recurrence rate in the patient with B-ALL; (a3) evaluation of a prognostic recurrence free survival rate in the patient with B-ALL; (a4) hierarchical diagnosis of B-ALL. The DIAPH1 gene is shown as the sequence 1 in the sequence table. According to the prognostic risk assessment marker for the B-ALL patient, the DIAPH1 gene mutation is found to be an independent risk factor for a cumulative relapse rate and a recurrence free survival rate of adult B-ALL patients. The invention may play an important role in the hierarchical diagnosis and prognosis evaluation of B-ALL.

Description

technical field [0001] The invention relates to a B-ALL patient prognosis risk assessment marker. Background technique [0002] B-lineage acute lymphoblastic leukemia (ALL) is the most common type of ALL in adults, and progress in risk stratification and treatment has significantly improved the prognosis of patients, but the recurrence rate of adult B-ALL is high, and the overall prognosis is still poor , long-term survival is only 30% -40%. The current risk stratification divides patients into standard risk and high risk based on age, initial white blood cell count, karyotype, central nervous system involvement, and response to initial treatment. However, it is worth noting that some of the standard-risk patients still relapsed, suggesting that the current risk stratification still needs to be refined, so the discovery and verification of new prognostic molecular markers is necessary for more accurate risk stratification , and may provide therapeutic targets. [0003] Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q2600/118C12Q2600/156
Inventor 阮国瑞黄晓军吴利新刘开彦
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com